Researchers uncover new approach for targeting p53
An alliance between industry and academia created by Cancer Research UK has discovered a new approach to targeting key cancer-linked proteins previously deemed ‘undruggable’.
Read More
Tag: p53
CR UK trials early-stage Lilly drug
Cancer Research UK has launched a new multi-site trial of an early-stage experimental therapy owned by Eli Lilly assessing its potential in a range of advanced cancers.
Read More
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
